Q3 EPS Estimates for Gossamer Bio Increased by HC Wainwright

Key Points

• HC Wainwright has increased its Q3 2025 EPS estimate for Gossamer Bio from ($0.16) to ($0.15), while the full-year estimate remains at ($0.28) per share.
• In its latest earnings report, Gossamer Bio beat analysts' expectations with a reported EPS of ($0.17), compared to the consensus estimate of ($0.18), along with revenues of $11.49 million against an expected $4.12 million.
• Gossamer Bio has received mixed analyst ratings, with one "sell," four "buy" ratings, and a consensus target price of $8.50, reflecting a moderate buy outlook from the market.

Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Research analysts at HC Wainwright upped their Q3 2025 earnings per share (EPS) estimates for shares of Gossamer Bio in a note issued to investors on Thursday, August 7th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.15) for the quarter, up from their prior forecast of ($0.16). The consensus estimate for Gossamer Bio's current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Gossamer Bio's FY2025 earnings at ($0.51) EPS, Q2 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.15) EPS and FY2027 earnings at ($0.05) EPS.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.01. The company had revenue of $11.49 million during the quarter, compared to analysts' expectations of $4.12 million. Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 344.81%.

A number of other equities research analysts have also issued reports on the stock. Wall Street Zen lowered shares of Gossamer Bio from a "hold" rating to a "sell" rating in a research note on Saturday. Wedbush upped their price objective on Gossamer Bio from $4.00 to $5.00 and gave the company an "outperform" rating in a research note on Wednesday, August 6th. The Goldman Sachs Group increased their target price on Gossamer Bio from $7.00 to $8.00 and gave the stock a "buy" rating in a report on Friday, May 16th. Finally, Scotiabank assumed coverage on Gossamer Bio in a report on Monday, July 14th. They issued a "sector outperform" rating and a $11.00 price target for the company. One analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.50.

Gossamer Bio Trading Up 1.1%

NASDAQ GOSS opened at $1.76 on Monday. The company has a market capitalization of $400.19 million, a price-to-earnings ratio of -2.84 and a beta of 1.96. The company has a debt-to-equity ratio of 6.70, a current ratio of 4.40 and a quick ratio of 4.40. Gossamer Bio has a 12 month low of $0.66 and a 12 month high of $2.23. The company's fifty day moving average price is $1.51 and its two-hundred day moving average price is $1.25.

Institutional Investors Weigh In On Gossamer Bio

Institutional investors and hedge funds have recently bought and sold shares of the business. Drive Wealth Management LLC boosted its stake in Gossamer Bio by 52.7% in the second quarter. Drive Wealth Management LLC now owns 25,474 shares of the company's stock valued at $31,000 after acquiring an additional 8,797 shares during the period. Graham Capital Management L.P. bought a new stake in shares of Gossamer Bio in the 4th quarter worth approximately $32,000. Virtu Financial LLC bought a new stake in shares of Gossamer Bio in the 1st quarter worth approximately $38,000. Fullcircle Wealth LLC acquired a new position in Gossamer Bio during the 4th quarter valued at approximately $43,000. Finally, ProShare Advisors LLC bought a new position in Gossamer Bio during the 2nd quarter worth $48,000. Institutional investors and hedge funds own 81.23% of the company's stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.